Pralatrexate - Latest Advances

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: June 29, 2025

Inhibition Of One-Carbon Metabolism In Ewing Sarcoma Results In Profound And Prolonged Growth Suppression Associated With Purine Depletion.

Journal: bioRxiv : the preprint server for biology

Published: May 16, 2025

One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth Suppression.

Journal: Cancer research communications

Published: April 24, 2025

Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo.

Journal: Antiviral research

Published: April 14, 2025

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Journal: Blood advances

Published: March 28, 2025

Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas.

Journal: Blood advances

Published: March 28, 2025

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Journal: Cancers

Published: January 31, 2025

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Journal: Discover oncology

Published: July 26, 2024

US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 25, 2024

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

Journal: Blood neoplasia

Published: July 01, 2024

The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity.

Journal: Frontiers in pharmacology

Published: June 17, 2024

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Journal: Leukemia & lymphoma

Published: March 22, 2024

Filters

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Inhibition Of One-Carbon Metabolism In Ewing Sarcoma Results In Profound And Prolonged Growth Suppression Associated With Purine Depletion.

Inhibition Of One-Carbon Metabolism In Ewing Sarcoma Results In Profound And Prolonged Growth Suppression Associated With Purine Depletion.

One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth Suppression.

One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth Suppression.

Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo.

Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo.

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas.

Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas.

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.

US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity.

The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity.

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.